Related Experiment Video
Updated: Jun 10, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
[Serum tumor markers for lung cancer diagnosis.]
Zikun Liang1, Shaofa Xu, Zhidong Liu
1Department of Thoracic Surgery,Beijing Institute of Tuberculosis and Thoracic Tumor. Beijing 101149,China. liangzikun@sina.com.
Background:
Progress has been made in research of lung cancer tumor markers in recent years,and these tumor markers have been used in clinical application. This study is to evaluate the regimens of six serum tumor markers in lung cancer diagnosis.
Methods:
The serum levels of the six tumor markers(NSE, pro-GRP, CYFRA21-1, SCC, p53 antibody and CA199) were detected in 80 healthy adults,170 patients with lung cancer and 80 patients with respiratory infection by ELISA.
Results:
The levels of the six tumor markers in patients with lung cancer were remarkably higher than those in healthy adults and patients with respiratory infection(P <0.01).The levels of the NSE,pro-GRP in patients with small cell lung cancer were significantly higher than those in other subtypes of the lung cancer(P <0.01);The levels of the CYFRA21-1,SCC in patients with squamous carcinoma was remarkably higher than that in other subtypes of the lung cancer(P <0.01).The sensitivity of the NSE,pro-GRP in diagnosing small cell lung cancer was remarkably higher than that in other subtypes of the lung cancer(P <0.01); The sensitivity of the CYFRA21-1, SCC in diagnosing squamous carcinoma was remarkably higher than that in other subtypes of the lung cancer(P <0.01).The sensitivity of the tumor markers combinations in diagnosing lung cancer was remarkably higher than that of the single marker (P <0.01).
Conclusions:
Detection of the six tumor markers is helpful for diagnosis lung cancer. Combination of NSE and pro-GRP is more economic than other combinations in diagnosing small cell lung cancer; Combined CYFRA21-1,SCC is more economic than other combinations in diagnosing squamous carcinoma.
